Organisation paid for research Program year 2025 Source: CMS Open Payments

Houston Methodist Research Institute

Neither a doctor nor a teaching hospital

Research payments

$9,599,519

386 payments

Through program year 2025, Houston Methodist Research Institute is reported as receiving $9,599,519 in research payments, across 386 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $687,840 34
2024 Research $354,606 91
2023 Research $3,993,278 94
2022 Research $1,118,678 30
2021 Research $1,807,290 44
2020 Research $1,620,622 83
2019 Research $17,205 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,955,536 4 payments
  2. Biogen, Inc. $1,743,946 14 payments
  3. Regeneron Pharmaceuticals, Inc. $1,429,453 38 payments
  4. Merck Sharp & Dohme Corporation $919,582 72 payments
  5. Ucb SA $542,629 23 payments
  6. Eisai Inc. $438,115 66 payments
  7. E.R. Squibb & Sons, L.L.C. $270,586 13 payments
  8. LivaNova USA, Inc. $214,915 4 payments
  9. Sumitomo Pharma America, Inc. $212,364 6 payments
  10. Paragonix Technologies, Inc. $153,777 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. MULTICENTER PHASE I/Ib TRIAL OF OLAPARIB IN COMBINATION WITH VORINOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY AND/OR METASTATIC BREAST CANCER $1,532,144 2 payments
  2. Multicenter Phase II Trial of Durvalumab with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer - DTP Trial $1,421,370 1 payment
  3. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 $906,545 18 payments
  4. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $778,115 2 payments
  5. A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in Participants with Incurable,Non-metastatic Hepatocellular Carcinoma LEAP-012 $648,925 18 payments
  6. Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease $621,172 2 payments
  7. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $356,487 11 payments
  8. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $260,780 22 payments
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease $254,517 1 payment
  10. A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension $218,868 7 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $60,320 2 payments
  2. Patient care $54,376 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record